Bottom line
JEHSX vs QAAGZX: the short answer
JEHSX (Health Sciences Trust) and QAAGZX (T. Rowe Price Health Sciences Portfolio) have nearly the same top holdings — their top 25 positions are about 96% the same by weight.
QAAGZX is cheaper at 0.86% vs 1.04% — a difference of $18 a year per $10,000 invested.
Over five years, JEHSX returned +4.2% a year vs +4.1% for QAAGZX.
Updated Nov 19, 2026
JEHSX vs QAAGZX side by side
| JEHSX | QAAGZX | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | John Hancock | T. Rowe Price |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.04% | 0.86% |
| Annual cost per $10k | $104 | $86 |
| 10-yr cost on $10k (prospectus) | $1,282 | $1,061 |
| Max front load | — | None |
| 12b-1 fee | 0.05% | 0% |
| 1-yr return | +19.5% | +18.1% |
| 5-yr return (annualized) | +4.2% | +4.1% |
| 10-yr return (annualized) | +8.7% | +9.0% |
| Best quarter | +23.6% | +23.4% |
| Worst quarter | −16.1% | −15.8% |
| Net assets (fund) | $251.3M | $751.7M |
| Number of holdings | 173 | 277 |
| Portfolio turnover | 68% | 65% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | JEHSX | QAAGZX | Difference |
|---|---|---|---|
| 2025 | +19.5% | +18.1% | +1.4% |
| 2024 | +1.8% | +1.7% | +0.1% |
| 2023 | +4.3% | +3.0% | +1.3% |
| 2022 | −13.1% | −12.5% | −0.6% |
| 2021 | +11.2% | +13.1% | −1.9% |
| 2020 | +27.2% | +29.6% | −2.5% |
| 2019 | +28.7% | +29.0% | −0.3% |
| 2018 | +0.7% | +1.1% | −0.4% |
| 2017 | +27.5% | +27.6% | −0.1% |
| 2016 | −10.6% | −10.5% | −0.1% |
Source: Fund prospectus bar charts
Holdings overlap
23 of JEHSX's top 25 holdings also appear in QAAGZX's top 25.
| Holding | JEHSX | QAAGZX |
|---|---|---|
| Eli Lilly and Company | 14.30% | 14.06% |
| Johnson and Johnson | 6.33% | 6.64% |
| UnitedHealth Group Incorporated | 5.95% | 5.88% |
| AbbVie Inc. | 5.28% | 5.12% |
| Merck and Co. Inc. | 4.21% | 4.00% |
| Gilead Sciences Inc. | 2.95% | 2.79% |
| Thermo Fisher Scientific Inc. | 2.67% | 2.53% |
| Vertex Pharmaceuticals Incorporated | 2.38% | 2.26% |
| Bristol-Myers Squibb Company | 2.22% | 2.12% |
| Abbott Laboratories | 2.00% | 1.91% |
| Intuitive Surgical Inc. | 1.98% | 1.89% |
| Amgen Inc. | 1.90% | 1.80% |
| Stryker Corporation | 1.87% | 1.78% |
| Elevance Health Inc. | 1.63% | 1.54% |
| Danaher Corporation | 1.51% | 1.44% |
Source: SEC Form N-PORT
JEHSX top 10
- Eli Lilly and Company — 14.30%
- Johnson and Johnson — 6.33%
- UnitedHealth Group Incorporated — 5.95%
- AbbVie Inc. — 5.28%
- Merck and Co. Inc. — 4.21%
- Gilead Sciences Inc. — 2.95%
- Thermo Fisher Scientific Inc. — 2.67%
- Vertex Pharmaceuticals Incorporated — 2.38%
- Bristol-Myers Squibb Company — 2.22%
- Abbott Laboratories — 2.00%
QAAGZX top 10
- Eli Lilly & Co — 14.06%
- Johnson & Johnson — 6.64%
- Unitedhealth Group Inc — 5.88%
- Abbvie Inc — 5.12%
- Merck & Co. Inc. — 4.00%
- Gilead Sciences Inc — 2.79%
- Thermo Fisher Scientific Inc — 2.53%
- Vertex Pharmaceuticals Inc — 2.26%
- Bristol-myers Squibb Co — 2.12%
- Abbott Laboratories — 1.91%
FAQ
What is the difference between JEHSX and QAAGZX?
Which is cheaper, JEHSX or QAAGZX?
Should I own both JEHSX and QAAGZX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.